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Novel Implantable Device to Detect Cardiac Allograft Rejection 
（心臓移植後拒絶反応を早期検知しうる機器の開発） 
 
論文要旨 
 
背景： 
臓器移植後の拒絶反応は、治療成績、予後を左右する重要な因子である。我々
の開発した Soul Mateは、移植後心臓に留置された電極線より得られた心筋心電
図をワイヤレスで送信のできる埋め込み型の機器である。本実験の目的は、送
信された心電図データを解析することにより、移植後の拒絶反応の早期検知を
可能とすることである。 
 
方法： 
5頭の犬に、異所心臓移植術を施行し同時に Soul Mateのモニター機器を埋め込
んだ。移植後、一定期間後に免疫抑制剤を中止し拒絶反応を誘発した。同時に
心筋生検を定期的に行い、拒絶反応の Gradeを病理診断した。Soul Mateから得
られた心筋心電図波形の 9個のパラメーター値の変化より、拒絶反応スコアを
計算し、病理結果と比較した。 
 
結果： 
5個のパラメーターより得られた拒絶反応スコアは、実際の病理診断と有意な相
関があった。さらに有意相関のあった 5パラメーターの中央値は、病理診断結
果と最も強い相関（r=0.939, p<0.001）が認められ、また、心筋生検病理にて拒
絶診断の得られる 1日前の時点で、感度 85.7%、特異度 100%で拒絶反応を検知
しえた。 
 
結論：動物実験モデルにおいて、Soul Mate拒絶反応モニター機器は、心臓移植
後の拒絶反応を非侵襲的に検知することが出来た。Soul Mateは、心臓移植後の
拒絶反応を、高頻度にかつ鋭敏に診断しうる機器として使用が可能であること
が示唆された。 
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1. Background 
 Each year approximately 5,000 patients worldwide undergo heart transplantation 
(HTx).  Despite improved immunosuppressive therapy, acute and chronic allograft 
rejection remains the most significant factor limiting the success of HTx.  Early, precise, 
and accurate detection of rejection, with subsequent effective management, is important 
to minimize allograft damage and prolong morbidity-free survival.  Currently, the most 
reliable technique for the diagnosis of acute allograft rejection is endomyocardial biopsy 
(EMB).  However, because of its cost, associated complications, invasiveness, and 
inability to completely survey the allograft, EMB falls quite short of optimal diagnosis 
of rejection and, more, does not allow for compulsive daily monitoring.  Also, EMB can 
be performed only in specialized centers, and results are not immediately available.  
Other simpler, less invasive, more sensitive methods for detecting rejection in real time 
are critically needed.  Electrical activity of the heart is closely related to its functional 
state, and analysis of intramyocardial electrocardiography (IMEG) has been considered 
sensitive and specific for allograft rejection [1-4].  The peak-to-peak amplitude (PPA) 
of the unipolar IMEG has been shown sensitive to a variety of alterations in myocardial 
physiology [1-6] but has been limited by the inability to easily transmit large quantities 
of continuous monitoring data.  Signal-averaged electrocardiography has helped in the 
management of HTx rejection in clinical applications [7-9], but it is difficult to perform 
and not frequently done. 
 TransWorld Heart™ Corporation (Charlotte, NC, USA) recently developed the 
Soul Mate® Heart Transplant Monitoring System to monitor electrophysiologic 
changes with the aim of allowing earlier diagnosis of graft rejection and help with acute 
and long-term patient management.  The Soul Mate uses wireless information 
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transmission to a centralized data reduction center with Internet accessible daily 
analysis of nine IMEG parameters recorded from six vectors of the heart.  The purpose 
of this study was to assess the efficacy of this novel device to detect cardiac allograft 
rejection nonivasively in a canine model.   
 
2. Methods 
2-1. Device Description 
 The Soul Mate Heart Transplant System (Figure 1) records and transfers IMEG 
data to the TransWorld Central Monitoring Center.  The Cardiac Rejection Monitoring 
Device (CRD™) records IMEG signals through three standard leads, at programmable 
times of up to 2 min in either bipolar or unipolar configurations.  One lead is placed on 
the epicardial surface of the right ventricle (RV) and two on the left ventricle (LV).  The 
device records information of the following nine IMEG parameters (Figure 2) from 
QRS complexes for each ventricular configuration at the frequency of 1,000 Hz: Area 
under dominant peak (AUDP) [mV • ms], area under minor peaks (AUMP) [mV • ms], 
area under the curve (AUC; sum of AUDP and AUMP) [mV • ms], base to dominant 
peak amplitude (BDPA) [mV], PPA [mV], nadir electrocardiogram duration (NED) 
[ms], total electrocardiogram duration (TED) [ms], slew rate of dominant peak upslope 
(SRDPU) [mV/ms], and slew rate of dominant peak downslope (SRDPD) [mV/ms]. 
Data transfer is achieved by holding the OneLife® Wand over the CRD, and 
stored data are transferred to the Wand via telemetry.  The data are then transferred 
from the Wand to the Home Call Box through a Bluetooth wireless connection.  For 
data analysis, the Home Call Box automatically sends the data to the Central Monitoring 
Center. 
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2-2. Experimental Design 
The study protocol was approved by the Cleveland Clinic’s Institutional Animal 
Care and Use Committee.  All animals received humane care in compliance with the 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources, Commission on Life Sciences, National Research Council, National 
Academy Press, Washington, D.C., 1996). 
Five mongrel dogs weighing 26.0 ± 1.6 kg underwent heterotopic cervical HTx 
[10-12], receiving allografts from five dogs weighing 8.9 ± 0.9 kg.  After the HTx and 
CRD implantation, data were collected and stored automatically by the CRD every 4-6 
h and transferred to the TransWorld Central Monitoring Center twice a day. 
Biopsy specimens were taken at regular intervals to determine biopsy rejection 
grade (BG), and the results were compared with analyzed data to evaluate the efficacy 
of the device. 
 
2-3. Surgical Procedures 
Donor dogs were anesthetized with 15 mg/kg of intravenous thiopental, 
ventilated through an endotracheal tube, and placed in the right lateral position.  
Through a left thoracotomy, the heart was harvested using potassium crystalloid 
cardioplegia and placed in cold saline.  An atrial septal defect was created by removing 
the foramen ovale, and the mitral leaflets were removed to create mitral regurgitation.  
Cardioplegia solution was injected every 20 min.   
The recipient dogs were anesthetized with 3 mg/kg of intravenous propofol, 
intubated and placed on the left side.  The right common carotid artery and external 
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jugular vein were exposed.  The brachiocephalic trunk of the donor dog’s explanted 
heart was anastomosed to the recipient’s carotid artery in an end-to-side fashion under 
systemic heparinization (100 U/kg).  The donor’s main pulmonary artery was 
anastomosed to the recipient’s right jugular vein.  After the HTx was completed, screw-
in myocardial leads were placed on the lateral wall and posterior wall of the LV and the 
RV free wall of the donor heart.  The leads were tunneled subcutaneously and attached 
to the CRD, which was placed in the subcutaneous pocket on the back of the animal. 
 
2-4. Immunosuppressive Protocol 
The animals were given methylprednisolone (500 mg) during the HTx procedure.  
On the day of the HTx, oral immunosuppressive therapy was started, consisting of 
cyclosporine (20 mg/kg/day) and prednisone (0.5 mg/kg/day).  The dosage of 
cyclosporine was adjusted to therapeutic blood levels between 400 and 600 ng/ml.  
Cyclosporine was discontinued at either 22 or 24 days after the HTx with exception of 
two animals that were sacrificed during this period of immunosuppressive therapy.  
Prednisone was continued at the same dose during the entire postoperative course to 
prevent rebound adrenal insufficiency. 
  
2-5. Surveillance EMB and Pathological Evaluation 
Follow-up biopsies were performed through an incision under local and general 
anesthesia.  Three to four full-layer biopsy specimens were taken from the ventricular 
septum with a biopsy needle (Tru-Cut Biopsy Needle, 18G, Cardinal Health) and fixed 
in 10% buffered formalin.  During the period of cyclosporine administration, a biopsy 
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study was performed three times per week.  After cessation of cyclosporine, daily 
biopsy studies were performed until the allograft stopped beating. 
All biopsy specimens were sectioned at three step levels, stained with 
hematoxylin and eosin and evaluated for the presence or absence of rejection by a 
cardiac pathologist, blinded to the status of immunosuppressive therapy, external 
findings of the allograft, and the data from the device.  BG was determined according to 
the revised classification scheme of the International Society for Heart and Lung 
Transplantation (ISHLT) [13].  In brief, rejection is classified as Grade 0R (none), 1R 
(mild), 2R (moderate), and 3R (severe).  
 
2-6. Data Analysis 
The median of the noninvasively transmitted IMEG values was obtained during 
each recording session for 1 day per lead configuration as representative of a single 
parameter for that day.  Two possible input sources were evaluated for each parameter, 
including the median of the normalized values obtained from six configurations (three 
ventricular leads in both unipolar and bipolar mode) and from four configurations, 
excluding the RV lead.  In addition, a calculation was performed by taking the 
parameter “General Median,” which was the median of the individual medians of the 
five parameters (AUC, AUDP, BDPA, PPA, and SRDPU) as input.  A sliding baseline 
consisted of the average values of one parameter over three consecutive days prior to 
the actual considered date.  Calculated rejection grade (CG) 2 was deemed to exist when 
the value of the parameter was between 50% and 70% of the baseline, and CG 3 when 
the value was lower than 50%.  When the value of a single parameter fell with an 
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average slope higher than 8% per day or the animal was in CG 2 or 3, the baseline 
remained frozen.  
 CGs were obtained each day and compared with BGs taken on the 
corresponding date.  Analysis was also performed between BG and CG just 1 day prior 
to the acquisition of biopsy data to determine the capability of the Soul Mate as an early 
rejection detecting device.  Correlation coefficients between BG and CG for each 
parameter were analyzed using SPSS software (version 11.5J, SPSS, Inc., Chicago, IL). 
 
2-7. Statement of Responsibility 
 I had full access to and take full responsibility for the integrity of the data.  All 
study participants have read and agree to the manuscript as written. 
 
3. Results 
The experimental course of each of the five animals, including ISHLT grades of 
rejection for biopsy specimens, is shown in Figure 3.  After the third post HTx day, 44 
biopsies were obtained.  Figure 4 shows representative histological findings of biopsy 
specimens taken from experimental animal 2 on day 2, 12, 28, and 31 postoperatively.  
These findings demonstrate no, mild, moderate, and severe rejection, respectively.  
During the experiments, 69,035 individual heartbeats were recorded and 
analyzed.  The six parameters (AUC, AUDP, BDPA, PPA, SRDPU, and General 
Median) successfully detected rejection in experiments 2 and 3.  In experiment 1, the six 
parameters reported grade 2 rejections not detected by biopsy on the day of the 
termination, although the allograft had stopped beating, probably because of ischemia 
caused by a thrombus in its aortic root.  In experiment 2, detection was 1 day earlier in 
   
   
7 
 
three parameters (AUD, AUDP and General Median) with four configurations, but there 
was one false-negative episode by the device on day 5.  In experiment 3, rapid 
progression of allograft rejection was observed, leading to complete graft failure and 
cardiac arrest on day 10.  Detection of rejection occurred 2 days earlier than by biopsy 
in six parameters with four configurations (not considering the RV lead).  In 
experiments 4 and 5, progressive rejection was not observed even after cessation of 
immunosuppressive therapy.  Figure 5 shows examples of the changes in 6 IMEG 
parameters with time after heart transplantation obtained in experiments 2, 3 and 5 from 
four configurations.  
Table 1 details the comparisons between BG and CG obtained through the 
General Median parameters from six configurations and four configurations.  When 
rejection grades are classified as negative (grade 0 or 1) or positive (grade 2 or 3), the 
corresponding diagnostic indices had a sensitivity of 85.7% and a specificity of 97.3% 
based on data from six configurations, and a sensitivity of 85.7% and a specificity of 
91.9% based on data from four configurations.  When BG was compared with CG, 
obtained 1 day prior to biopsy, the indices had a sensitivity of 71.4% and a specificity of 
100% based on data from six configurations, and a sensitivity of 85.7% and a specificity 
of 100% based on data from four configurations.  In Table 2, correlation coefficients 
between CG and BG using each parameter are shown.  Significant correlations (r > 0.75, 
p < 0.001) were obtained between the biopsy results and the six parameters (AUC, 
AUDP, BDPA, PPA, SRDPU, and General Median).  In the rest of the four parameters, 
there were no correlations higher than 0.7.  The strongest correlation (r = 0.939) was 
obtained using the General Median with four configurations 1 day prior to obtaining the 
biopsy data. 
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4. Discussion 
A decline in R-wave amplitude from a surface 12-lead electrocardiogram has 
been considered indicative of organ rejection since the early years of HTx.  This decline 
likely reflects a decrease in functional myocardial cell mass as a result of myocyte 
injury and necrosis, which occurs with moderate to severe inflammation caused by 
rejection.  Several reports suggest that IMEG recordings are more sensitive and specific 
for diagnosing graft rejection [1-6, 11].  Recently, IMEG monitoring has been clinically 
applied for patient management after HTx [14-16]; however, the Soul Mate system has 
several significant advantages over this method, as it can measure, analyze, and transmit 
nine IMEG parameters from six vectors.  Of nine parameters, five were significantly (r 
> 0.75, p < 0.001) correlated to biopsy results and demonstrated the Soul Mate’s ability 
to make an early diagnosis of allograft rejection.  By applying the General Median 
parameter, the strongest correlation coefficient was obtained when BG was compared 
with CG obtained 1 day prior to biopsy.  The sensitivity of 85.7% and specificity of 
100% to determine biopsy-proven cardiac allograft rejection demonstrated the 
capability of this device to more effectively and safely monitor heart transplant patients.  
Indeed, we believe that the ability of this device to provide more frequent recording of 
parameters that characterize allograft rejection will allow earlier diagnosis of significant 
rejection episodes requiring ad hoc immunosuppressive therapies as well as critical fine-
tuning of day-to-day maintenance immunosuppressive strategies.   
Unfortunately, contemporary management of patients post HTx relies primarily 
on a “cookbook” approach, with standard multidrug protocols usually prescribed to 
prevent rejection and maintain graft integrity and optimal function.  Immunosuppressive 
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drugs, however, are toxic and cause renal and hepatic insufficiency as well as the risk of 
infection and malignancy in these patients that is directly related to the degree of 
immunosuppression prescribed [17].  Management of immunosuppressive strategies by 
EMB does not enable daily fine tuning of drug administration and doses that follow a 
minimalist strategy.  The Soul Mate can fulfill this challenge.  Indeed, it reported 
rejection not detected by biopsy on the days of experiment termination.  In the absence 
of significant cellular rejection, allograft failure in this animal could be explained by 
ischemia from the autopsy findings.  However, it may also be explained by the 
occurrence of antibody-mediated rejection, which, without additional 
immunohistochemical stains, routine EMB cannot detect.  Indeed, in a previous animal 
study [12], the sensitivity of IMEG was much higher than that of EMB (100% vs. 
12.5%) to detect antibody-mediated rejection. 
For early detection of rejection, six parameters with four configurations (not 
considering the RV lead) appear to have provided the best results.  In contrast, Everett 
and associates [6] concluded that the sensitivity of detecting rejection increased with the 
increase in the number of leads, using unipolar PPA as a parameter in their animal study.  
We believe that using the input source without considering the RV lead enables earlier 
detection of rejection.  
One important limitation of this study is that we employed a heterotopic rather 
than an orthotopic HTx model.  The effects of preload and afterload on the course of 
allograft rejection can be debated.  Since the primary purpose of our experiment was to 
prove the concept that IMEG can detect and quantitate cardiac allograft rejection, we 
preferred this approach because the graft would not be burdened by the need to maintain 
an adequate hemodynamic load to sustain animal survival.  Another limitation may be 
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the fact that the immunosuppressive therapy used in this study was not entirely 
consistent with that employed in humans and that the donor dogs were not crossmatched 
with recipient dogs.  The allograft in experiment 3 suffered from severe rejection and 
stopped beating on day 10, even though therapeutic cyclosporine blood concentration 
levels were noted and would have been predicted to have prevented this event (Figure 3).  
In contrast, the allograft in experiment 4 demonstrated only mild rejection 9 days after 
the cessation of cyclosporine.  Another limitation is that the optimum "cut offs" to 
determine CG grades (>50 and 70% baseline) and the 5 IMEG parameters used to 
derive General Median parameter were determined after the study.  Also these 
optimized values are specific to this animal model and may be different for human 
transplant rejection.  Further studies, especially in human, will be necessary to validate 
the proper cut offs and the IMEG parameters for the General Median calculation. 
Finally, the number of animals was small, and the duration of each experiment 
was short.  Further studies are warranted to evaluate the effects of myocardial and 
electrode fibrosis changes, diastology changes, ischemia (transplant vasculopathy), 
and/or infection on the sensitivity and accuracy of chronic IMEG parameter 
measurements to detect rejection.  In addition, the effects of therapeutic interventions 
(such as bolus steroids) on the IMEG parameters have to be evaluated.  To further 
validate results, human clinical trials would be a next step, given the probable safety of 
the device as extrapolated from experiences with simple pacemakers and defibrillators 
in HTx patients and demonstration that the unit can detect and monitor acute rejection, 
as well as transmit data via telemetry. 
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5. Conclusions 
 We conclude that the Soul Mate cardiac allograft rejection monitoring system 
demonstrated the capability, in real time, to accurately and noninvasively detect early 
acute allograft rejection in a heterotopic canine model.  This approach could be used as 
a noninvasive tool for guiding the frequency and timing of obtaining an EMB.  This 
device would potentially reduce the number of biopsies needed and result in earlier 
detection and treatment of rejection.  Indeed, it is possible that the device could actually 
replace EMBs and allow vastly more frequent allograft rejection assessment that would 
assist the clinician with day-to-day, evidence-based adjustments of complicated and 
toxic immunosuppression cocktails.  Further, using the transtelephonic measurements 
could be beneficial for patients who can be monitored at great distances from the 
transplant center.  There is a potential that the Soul Mate system would offer a method 
for less invasive and more effective management of HTx patients.  
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8. Figures 
8-1. Figure 1.  The components of the Soul Mate Heart Transplant System. 
 
 
 
 
 
 
8-2. Figure 2.  Nine IMEG parameters, recorded and analyzed. 
 
   
16 
 
 
 8-3. Figure 3.  Summary of the experimental time course of the five dogs.  In 
experiments 1 and 3, the animal was sacrificed before the cessation of the cyclosporine 
regimen.  In experiments 2, 4, and 5, cyclosporine administration was stopped on POD 24, 
24, and 22, respectively.  D/C, discontinuance; POD, postoperative day. 
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 8-4. Figure 4.  Histological findings from biopsy specimens (experiment 2).  These 
slides from postoperative days (POD) 2, 12, 28, and 31 after HTx are representative of no 
rejection, mild rejection, moderate rejection, and severe rejection, respectively (hematoxylin 
and eosin × 400). 
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 8-5. Figure 5.  The daily changes in the ratio of the 6 individual IMEG parameters 
over their sliding baseline in the cases where rejection occurred (Figure 5a: Experiment 2 
and Figure 5b: Experiment 3) and in the case where rejection did not occur (Figure 5c: 
Experiment 5).  The y axis value is a measure of the degree of increase or decrease in the 
recorded IMEG parameter from its sliding baseline (average value recorded over the 
previous 3 days). The black vertical line indicates the day when immunosuppression was 
ceased.  CG in the x-axis is from General Median data. 
 
Figure 5a 
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Figure 5b 
 
 
Figure 5c 
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9. Tables 
9-1. Table 1.  Comparison between biopsy grade and calculated grade 
Configuration/Parameter CG 0 or 1 CG 2 CG 3 
Six configurations 
BG 0 
BG 1 
BG 2 
BG 3 
 
7 
19 
1 
0 
 
1 
0 
2 
1 
 
0 
0 
0 
3 
Four configurations 
BG 0 
BG 1 
BG 2 
BG 3 
 
7 
27 
1 
0 
 
1 
2 
1 
0 
 
0 
0 
1 
4 
Six configurations 
(1 day prior to biopsy) 
BG 0 
BG 1 
BG 2 
BG 3 
 
 
8 
29 
2 
0 
 
 
0 
0 
1 
3 
 
 
0 
0 
0 
1 
Four configurations 
(1 day prior to biopsy) 
BG 0 
BG 1 
BG 2 
BG 3 
 
 
8 
29 
1 
0 
 
 
0 
0 
2 
1 
 
 
0 
0 
0 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CG, calculated rejection grade; BG, biopsy rejection grade 
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9-2. Table 2.  Correlation coefficient results 
Config-
urations 
 
AUC 
 
AUDP 
 
BDPA 
 
PPA 
 
SRDPU 
General 
median 
 
AUMP 
 
NED 
 
TED 
 
SRDPD 
6 Conf.a      0.834** 0.833** 0.885** 0.870** 0.832** 0.885** 0.122 0.354* 0.550** 0.551** 
4 Conf.b 0.787** 0.834** 0.896** 0.817** 0.837** 0.820** -0.228 -0.009 0.550** 0.571** 
6 Conf.  
   day-1c 
0.869** 0.931** 0.881** 0.881** 0.763** 0.881** 0.175 0.387* 0.397* 0.628** 
4 Conf.  
   day-1d 
0.884** 0.931** 0.890** 0.881** 0.852** 0.939** -0.17 0.084 0.397* 0.628** 
 
Correlation coefficient using the data obtained from 
a
all six configurations, 
b
four 
configurations excluding the RV lead, 
c
all six configurations 1 day prior to the biopsy data, 
and 
d
four configurations, excluding the RV lead, 1 day prior to the biopsy data. 
AUC, area under the curve; AUDP, area under dominant peak; BDPA, base to dominant 
peak amplitude; PPA. peak to peak amplitude; SRDPU, slew rate of dominant peak upslope; 
AUMP, area under minor peaks; NED, nadir electrocardiogram duration; TED. total 
electrocardiogram duration; SRDPD, slew rate of dominant peak downslope. 
The data in bold indicate r > 0.75 
*p < 0.05, **p < 0.001 
 
